These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32327159)

  • 1. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
    Al-Omar HA; Alghannam HH; Aljuffali IA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
    Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.
    Rotar AM; Preda A; Löblová O; Benkovic V; Zawodnik S; Gulacsi L; Niewada M; Boncz I; Petrova G; Dimitrova M; Klazinga N
    Health Policy; 2018 Mar; 122(3):230-236. PubMed ID: 29373186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
    Robinson MF; Mihalopoulos C; Merlin T; Roughead E
    Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
    Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
    Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
    Ferrario A; Arāja D; Bochenek T; Čatić T; Dankó D; Dimitrova M; Fürst J; Greičiūtė-Kuprijanov I; Hoxha I; Jakupi A; Laidmäe E; Löblová O; Mardare I; Markovic-Pekovic V; Meshkov D; Novakovic T; Petrova G; Pomorski M; Tomek D; Voncina L; Haycox A; Kanavos P; Vella Bonanno P; Godman B
    Pharmacoeconomics; 2017 Dec; 35(12):1271-1285. PubMed ID: 28836222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrative Review of Managed Entry Agreements: Chances and Limitations.
    Zampirolli Dias C; Godman B; Gargano LP; Azevedo PS; Garcia MM; Souza Cazarim M; Pantuzza LLN; Ribeiro-Junior NG; Pereira AL; Borin MC; de Figueiredo Zuppo I; Iunes R; Pippo T; Hauegen RC; Vassalo C; Laba TL; Simoens S; Márquez S; Gomez C; Voncina L; Selke GW; Garattini L; Kwon HY; Gulbinovic J; Lipinska A; Pomorski M; McClure L; Fürst J; Gambogi R; Ortiz CH; Canuto Santos VC; Araújo DV; Araujo VE; Acurcio FA; Alvares-Teodoro J; Guerra-Junior AA
    Pharmacoeconomics; 2020 Nov; 38(11):1165-1185. PubMed ID: 32734573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.
    Novakovic T; Martin AP; Parker M; Ferrario A; Vukovic S; Łanda K; Duba J; Dankó D; Kotsopoulos N; Godman B; Ristic J; Stefanovic D; Tesic D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):519-521. PubMed ID: 28946800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.
    Eichler HG; Adams R; Andreassen E; Arlett P; van de Casteele M; Chapman SJ; Goettsch WG; Martinsson JL; Llinares-Garcia J; Nachtnebel A; Pean E; Rasi G; Reksten TR; Timmers L; Vreman RA; van de Vijver I; Wenzl M
    Int J Technol Assess Health Care; 2021 Aug; 37(1):e83. PubMed ID: 34424152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
    Toumi M; Jarosławski S; Sawada T; Kornfeld Å
    Appl Health Econ Health Policy; 2017 Feb; 15(1):5-11. PubMed ID: 27581118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries.
    Efthymiadou O
    Eur J Health Econ; 2023 Sep; 24(7):1023-1031. PubMed ID: 36219363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
    Shobeiri N; Peiravian F; Yousefi N
    Iran J Pharm Res; 2022 Dec; 21(1):e126916. PubMed ID: 36060922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.